利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.018 秒)

    BLOOD MARKER FOR RENAL CANCER
    1.
    发明申请
    BLOOD MARKER FOR RENAL CANCER 审中-公开
    血液肿瘤标志物

    公开(公告)号：US20150044691A1

    公开(公告)日：2015-02-12

    申请号：US14523658

    申请日：2014-10-24

    申请人： Shimadzu Corporation ,  Educational Corporation Mukogawa Gakuin ,  Hyogo College of Medicine

    发明人： Eiichi Matsuo ,  Naoki Kaneko ,  Makoto Watanabe ,  Osamu Nishimura ,  Noboru Okamura ,  Akinobu Gotoh

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57438 ,  C12N9/96 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/988

    摘要： The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.

    摘要翻译： 本发明提供了用于肾癌的血液标志物，更具体地，可以实际用于肾癌的临床诊断的血液标志物。 本发明还提供了一种血液标志物，其可以实际用于治疗之后的后续，例如手术和治疗期间，例如用于肾癌的药物。 选自Galectin-1，Galectin-3和α-烯醇化酶的肾癌血液标志物。 Galectin-1和/或Galectin-3作为肾癌的血液标志物，用于在诊断成像之前进行的检查。 α-烯醇化酶作为用于肾癌治疗期间和/或治疗期间的肾癌的血液标志物。

    BLOOD MARKER FOR RENAL CANCER
    2.
    发明申请
    BLOOD MARKER FOR RENAL CANCER 审中-公开
    血液肿瘤标志物

    公开(公告)号：US20130171660A1

    公开(公告)日：2013-07-04

    申请号：US13728932

    申请日：2012-12-27

    申请人： SHIMADZU CORPORATION ,  EDUCATIONAL CORPORATION MUKOGAWA GAKUIN ,  HYOGO COLLEGE OF MEDICINE

    发明人： Eiichi Matsuo ,  Naoki Kaneko ,  Makoto Watanabe ,  Osamu Nishimura ,  Noboru Okamura ,  Akinobu Gotoh

    IPC分类号： G01N33/68 ,  C12N9/96

    CPC分类号： G01N33/57438 ,  C12N9/96 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/988

    摘要： The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.

    摘要翻译： 本发明提供了用于肾癌的血液标志物，更具体地，可以实际用于肾癌的临床诊断的血液标志物。 本发明还提供了一种血液标志物，其可以实际用于治疗之后的后续，例如手术和治疗期间，例如用于肾癌的药物。 选自Galectin-1，Galectin-3和α-烯醇化酶的肾癌的血液标志物。 Galectin-1和/或Galectin-3作为肾癌的血液标志物，用于在诊断成像之前进行的检查。 α-烯醇化酶作为用于肾癌治疗期间和/或之后的监测用于肾癌的血液标志物。

    MULTIPLEX COLON CANCER MARKER PANEL
    4.
    发明申请
    MULTIPLEX COLON CANCER MARKER PANEL 审中-公开
    多功能殖民地癌症标志物面板

    公开(公告)号：US20130165340A1

    公开(公告)日：2013-06-27

    申请号：US13723133

    申请日：2012-12-20

    申请人： SHIMADZU CORPORATION ,  OSAKA UNIVERSITY

    发明人： Makoto Watanabe ,  Eiichi Matsuo ,  Naoki Kaneko ,  Toshiya Matsubara ,  Osamu Nishimura ,  Masaki Mori ,  Hideo Matsuda ,  Shigeto Seno ,  Ichiro Takemasa

    IPC分类号： G01N33/68

    CPC分类号： G01N33/57419 ,  G01N33/6893

    摘要： The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2.A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

    摘要翻译： 本发明提供了基于统计知识的结肠癌标志物的特异性组合，其能够在保持高特异性的同时检测较早数量的结肠癌患者。 包括癌胚抗原相关细胞粘附分子5，碳水化合物抗原19-9，半乳凝素-4，APEX核酸酶和肌动蛋白相关蛋白2的五个结肠癌标志物的组合的多重结肠癌标志物。2.一种分析结肠癌标志物的方法 使用多重结肠癌标记物。